Conference Coverage
News
EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestations
The update builds on 2019 recommendations and incorporates safety concerns about JAK inhibitors, advises on differential drug efficacy across...
Conference Coverage
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsA
Patients with axial spondyloarthritis and psoriatic arthritis who used JAK inhibitors did not have higher risk of myocardial infarction or stroke...
Conference Coverage
Are repeat radiographs necessary in rheumatoid and psoriatic arthritis?
“If a patient doesn’t achieve remission or very low disease activity, obtaining a radiograph doesn’t change what you do because the patient’s not...
Conference Coverage
PsA prediction tool approaches clinical utility
A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.
News
Topical psoriasis treatments
When using topical treatments, combination therapy is generally more effective than monotherapy for psoriasis, especially for plaque psoriasis, Dr...
News
New ACR vaccination guideline: Take your best shot
Vaccinate patients with rheumatic and musculoskeletal disease against flu and other vaccine-preventable disease whenever possible, experts say.
Conference Coverage
Retention rates high after biosimilar-to-biosimilar switch for inflammatory arthritis
Danish investigators studied how a government-mandated switch from one infliximab biosimilar to another affected patients with inflammatory...
News
Practical pearls guide treatment of psoriasis in tricky areas
Start by ensuring the correct diagnosis, then take advantage of the expanding arsenal of therapies, Dr. Jennifer Soung advised.
Conference Coverage
Sex differences seen in inflammatory arthritis health care use
Women’s higher risk of conditions such as osteoarthritis and pain and fatigue may help to explain why overall healthcare resource use was higher...
News
Apremilast alleviates severe psoriasis in some children, data show
“In this randomized, placebo-controlled trial, oral apremilast demonstrated effectiveness and was well tolerated.”